23.75
Edgewise Therapeutics Inc 주식(EWTX)의 최신 뉴스
Aug Ideas: Can Edgewise Therapeutics Inc stock hit record highs againWeekly Investment Report & Momentum Based Trading Signals - moha.gov.vn
Edgewise Therapeutics (EWTX) Stock News, Forecasts and Analysis: What’s Driving the December 2025 Move and What Comes Next - ts2.tech
Edgewise Therapeutics (EWTX) Stock: Latest News, Analyst Forecasts, and What’s Driving the December 2025 Surge - ts2.tech
Edgewise Therapeutics stock steady midday after $3 million insider sale filing — what’s next for EWTX - ts2.tech
Edgewise Therapeutics (NASDAQ:EWTX) Shares Gap DownHere's What Happened - MarketBeat
Analysts Are Bullish on These Healthcare Stocks: Vertex Pharmaceuticals (VRTX), Edgewise Therapeutics (EWTX) - The Globe and Mail
Valuation Update: Is Edgewise Therapeutics Inc stock a top pick in earnings seasonMarket Trend Report & Verified Entry Point Detection - moha.gov.vn
This Biotech Fund Exited an $8 Million Edgewise Stake as the Stock Slid Double Digits - The Globe and Mail
Edgewise: Maintaining Buy On Part D EDG-7500 Data And Next Q2 2026 Catalyst (NASDAQ:EWTX) - Seeking Alpha
What drives Edgewise Therapeutics Inc stock priceHigh Dividend Yield Stocks & Free Trading Signals to Sharpen Your Edge - earlytimes.in
Edgewise Therapeutics (NASDAQ:EWTX) Cut to Sell at Wall Street Zen - MarketBeat
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Edgewise Therapeutics (EWTX) Stock Today: EDG-7500 Safety Update, Analyst Targets, and What Investors Are Watching Next - ts2.tech
Edgewise Therapeutics (NASDAQ:EWTX) Trading Down 5.2%Here's Why - MarketBeat
Edgewise Therapeutics (EWTX) Stock Surges on EDG-7500 Safety Update as Wall Street Prepares to Reopen After Christmas - ts2.tech
Medpace and Edgewise Therapeutics Advance Becker Muscular Dystrophy Study - MSN
Edgewise Therapeutics Announces Completion of the EDG-7500 CIRRUS-HCM Phase 2 Parts B and C and Favorable Interim Safety Results from the Ongoing Part D Study in Hypertrophic Cardiomyopathy - BioSpace
Edgewise Therapeutics Stock Jumps After Trial Update For Genetic Heart Disease — Wall Street Eyes A Potential Standout - Stocktwits
Edgewise Therapeutics (EWTX): Assessing Valuation After an 80% Three-Month Surge in the Share Price - Yahoo Finance
Edgewise Stock (+26%): Phase 2 HCM Safety Data Forces a Re-Rate - Trefis
Why Edgewise Therapeutics Stock Rocked the Market Today - Finviz
Why Edgewise Therapeutics Stock Rocked the Market Today - The Motley Fool
Edgewise Therapeutics: Differentiated EDG-7500 Profile, Late-Stage Cardiology Catalyst, and Expanding Pipeline Support Buy Rating - TipRanks
Edgewise Therapeutics Stock (EWTX) Jumps on EDG-7500 CIRRUS-HCM Update: Dec. 24, 2025 News, Analyst Forecasts, and Key Catalysts - ts2.tech
Edgewise Therapeutics (NASDAQ:EWTX) Shares Gap UpHere's What Happened - MarketBeat
Edgewise Therapeutics rises on positive safety data from heart disease drug trial - TradingView — Track All Markets
Edgewise posts trial data for heart disease drug (EWTX:NASDAQ) - Seeking Alpha
Edgewise Therapeutics Shares Rise After Advancing Phase 2 Hypertrophic Cardiomyopathy Trial - marketscreener.com
Why Is Edgewise Therapeutics Stock Soaring Wednesday? - Benzinga
Edgewise reports positive interim safety data for HCM drug EDG-7500 - Investing.com Nigeria
Edgewise Therapeutics stock rises on positive HCM drug update By Investing.com - Investing.com Nigeria
Edgewise Therapeutics stock rises on positive HCM drug update - Investing.com
Edgewise Therapeutics Announces Completion of the EDG-7500 CIRRU - GuruFocus
Edgewise Completed Phase 2 CIRRUS-HCM Parts B And C, Reports Favorable Interim Safety From Part D - Nasdaq
Edgewise Therapeutics Completes Parts B and C of Phase 2 Hypertrophic Cardiomyopathy Trial - marketscreener.com
Edgewise reports positive interim safety data for HCM drug EDG-7500 By Investing.com - Investing.com South Africa
Edgewise Therapeutics Inc on track to deliver full 12-week part D readout in 2Q 2026 and phase 3 start in 4Q 2026 - marketscreener.com
Edgewise Therapeutics Inc On Track To Deliver Full 12-Week Part D Readout In 2Q 2026 And Phase 3 Start In 4Q 2026 - TradingView — Track All Markets
Edgewise Therapeutics Announces Completion of the EDG-7500 Cirrus-HCM Phase 2 Parts B and C and Favorable Interim Safety Results from the Ongoing Part D Study in Hypertrophic Cardiomyopathy - marketscreener.com
Insider Trends: Is Edgewise Therapeutics Inc stock vulnerable to regulatory risksQuarterly Profit Summary & Expert Curated Trade Setups - moha.gov.vn
Can Edgewise Therapeutics Inc. stock double in next 5 yearsLow Beta Stocks & Use Smart Algorithms to Pick Better Stocks - bollywoodhelpline.com
Edgewise Therapeutics (EWTX) Stock News Today: What’s Driving the Volatility, Analyst Forecasts, and Key Catalysts (Dec. 22, 2025) - ts2.tech
자본화:
|
볼륨(24시간):